Literature DB >> 24277735

Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis.

Chiara Fenoglio1, Elisa Ridolfi, Claudia Cantoni, Milena De Riz, Rossana Bonsi, Maria Serpente, Chiara Villa, Anna M Pietroboni, Robert T Naismith, Enrique Alvarez, Becky J Parks, Nereo Bresolin, Anne H Cross, Laura M Piccio, Daniela Galimberti, Elio Scarpini.   

Abstract

Emerging evidence underlines the importance of micro(mi)RNAs in the pathogenesis of multiple sclerosis (MS). Free-circulating miRNAs were investigated in serum from MS patients compared to controls. Statistically significant decreased levels of miR-15b, miR-23a and miR-223 were observed in MS patients (p < 0.05). Results were validated and replicated in two further independent MS populations. A direct correlation between miRNA levels and the EDSS score was determined in PPMS (p < 0.007). The generalized trend toward miRNA down-regulation could result in over-expression of target genes involved in disease pathogenesis. Circulating miRNA profiling could thus represent a new avenue to identify easily detectable disease biomarkers.

Entities:  

Keywords:  Multiple sclerosis; biomarkers; demyelination; microRNA; serum

Mesh:

Substances:

Year:  2013        PMID: 24277735     DOI: 10.1177/1352458513485654

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  35 in total

Review 1.  Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Authors:  Charlotte E Teunissen; Arjan Malekzadeh; Cyra Leurs; Claire Bridel; Joep Killestein
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

2.  Multiple sclerosis patient-derived CSF induces transcriptional changes in proliferating oligodendrocyte progenitors.

Authors:  Jeffery D Haines; Oscar G Vidaurre; Fan Zhang; Ángela L Riffo-Campos; Josefa Castillo; Bonaventura Casanova; Patrizia Casaccia; Gerardo Lopez-Rodas
Journal:  Mult Scler       Date:  2015-05-06       Impact factor: 6.312

Review 3.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

4.  Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Claudia Cantoni; Francesca Cignarella; Laura Ghezzi; Bob Mikesell; Bryan Bollman; Melissa M Berrien-Elliott; Aaron R Ireland; Todd A Fehniger; Gregory F Wu; Laura Piccio
Journal:  Acta Neuropathol       Date:  2016-10-04       Impact factor: 17.088

Review 5.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

6.  Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.

Authors:  William J Magner; Bianca Weinstock-Guttman; Mina Rho; David Hojnacki; Rabia Ghazi; Murali Ramanathan; Thomas B Tomasi
Journal:  J Neuroimmunol       Date:  2016-01-21       Impact factor: 3.478

7.  MEG3 modulates TIGIT expression and CD4 + T cell activation through absorbing miR-23a.

Authors:  Jianhong Wang; Xiangxiang Liu; Caixia Hao; Yingjuan Lu; Xiaohui Duan; Rong Liang; Guangxun Gao; Tao Zhang
Journal:  Mol Cell Biochem       Date:  2018-10-31       Impact factor: 3.396

8.  MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression.

Authors:  Roberta Mancuso; Ambra Hernis; Simone Agostini; Marco Rovaris; Domenico Caputo; Mario Clerici
Journal:  J Transl Med       Date:  2015-05-07       Impact factor: 5.531

Review 9.  Role of Thioredoxin-Interacting Protein in Diseases and Its Therapeutic Outlook.

Authors:  Naila Qayyum; Muhammad Haseeb; Moon Suk Kim; Sangdun Choi
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

10.  Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b.

Authors:  Jens Ingwersen; Til Menge; Britta Wingerath; Derya Kaya; Jonas Graf; Tim Prozorovski; Andreas Keller; Christina Backes; Markus Beier; Matthias Scheffler; Thomas Dehmel; Bernd C Kieseier; Hans-Peter Hartung; Patrick Küry; Orhan Aktas
Journal:  Ann Clin Transl Neurol       Date:  2014-12-05       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.